EP4074344A1 — Targeting lipids
Assigned to Arbutus Biopharma Corp · Expires 2022-10-19 · 4y expired
What this patent protects
The present invention provides targeting lipids of structure (CI) L<sup>100</sup> - linker - L<sup>101</sup>, where L<sup>100</sup> is a lipid, lipophile, alkyl, alkenyl or alkynyl, L<sup>101</sup> is a ligand or -CH<sub>2<…
USPTO Abstract
The present invention provides targeting lipids of structure (CI) L<sup>100</sup> - linker - L<sup>101</sup>, where L<sup>100</sup> is a lipid, lipophile, alkyl, alkenyl or alkynyl, L<sup>101</sup> is a ligand or -CH<sub>2</sub>CH<sub>2</sub>(OCH<sub>2</sub>CH<sub>2</sub>)<sub>p</sub>O(CH<sub>2</sub>)<sub>q</sub>CH<sub>2</sub>-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.